Switch theme
Sign up to access all valuation multiples
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
1956
991
LTM Revenue $241M
LTM EBITDA $61.9M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sanofi India has a last 12-month revenue (LTM) of $241M and a last 12-month EBITDA of $61.9M.
In the most recent fiscal year, Sanofi India achieved revenue of $233M and an EBITDA of $55.2M.
Sanofi India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sanofi India valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $241M | XXX | $233M | XXX | XXX | XXX |
| Gross Profit | $126M | XXX | $116M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $61.9M | XXX | $55.2M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $58.8M | XXX | $53.1M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $44.3M | XXX | $48.4M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sanofi India's stock price is INR 6209 (or $73).
Sanofi India has current market cap of INR 143B (or $1.7B), and EV of INR 140B (or $1.6B).
See Sanofi India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.7B | XXX | XXX | XXX | XXX | $1.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sanofi India has market cap of $1.7B and EV of $1.6B.
Sanofi India's trades at 7.1x EV/Revenue multiple, and 29.8x EV/EBITDA.
Equity research analysts estimate Sanofi India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sanofi India has a P/E ratio of 37.8x.
See valuation multiples for Sanofi India and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 26.5x | XXX | 29.8x | XXX | XXX | XXX |
| EV/EBIT | 28.0x | XXX | 30.9x | XXX | XXX | XXX |
| EV/Gross Profit | 13.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.8x | XXX | 34.6x | XXX | XXX | XXX |
| EV/FCF | 39.4x | XXX | 33.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanofi India's last 12 month revenue growth is 6%
Sanofi India's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Sanofi India's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sanofi India's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sanofi India and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | -19% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanofi India acquired XXX companies to date.
Last acquisition by Sanofi India was XXXXXXXX, XXXXX XXXXX XXXXXX . Sanofi India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sanofi India founded? | Sanofi India was founded in 1956. |
| Where is Sanofi India headquartered? | Sanofi India is headquartered in India. |
| How many employees does Sanofi India have? | As of today, Sanofi India has 991 employees. |
| Is Sanofi India publicy listed? | Yes, Sanofi India is a public company listed on BOM. |
| What is the stock symbol of Sanofi India? | Sanofi India trades under 500674 ticker. |
| When did Sanofi India go public? | Sanofi India went public in 1991. |
| Who are competitors of Sanofi India? | Similar companies to Sanofi India include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sanofi India? | Sanofi India's current market cap is $1.7B |
| What is the current revenue of Sanofi India? | Sanofi India's last 12 months revenue is $241M. |
| What is the current revenue growth of Sanofi India? | Sanofi India revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Sanofi India? | Current revenue multiple of Sanofi India is 6.8x. |
| Is Sanofi India profitable? | Yes, Sanofi India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sanofi India? | Sanofi India's last 12 months EBITDA is $61.9M. |
| What is Sanofi India's EBITDA margin? | Sanofi India's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Sanofi India? | Current EBITDA multiple of Sanofi India is 26.5x. |
| What is the current FCF of Sanofi India? | Sanofi India's last 12 months FCF is $41.7M. |
| What is Sanofi India's FCF margin? | Sanofi India's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Sanofi India? | Current FCF multiple of Sanofi India is 39.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
